Dhaka, Bangladesh

Kakon Nag

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Globe Biotech Limited. Active years: 2025.

USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Kakon Nag: Innovator in Coronavirus Vaccine Development

Introduction

Kakon Nag is a prominent inventor based in Dacca, Bangladesh. He has made significant contributions to the field of biotechnology, particularly in the development of vaccines. His innovative work focuses on combating the coronavirus and its variants.

Latest Patents

Kakon Nag holds a patent for a vaccine designed for use against coronavirus and its variants. This novel transgene is engineered to produce a coronavirus vaccine and includes several key components. The transgene encodes an RNA polymerase promoter, a 5' UTR, a secretory sequence, a coronavirus spike protein component with a variant sequence at amino acid position 614, and a 3′ UTR along with a poly A sequence. Additionally, the patent provides a vaccine that comprises the transgene or an mRNA transcript derived from it.

Career Highlights

Kakon Nag is associated with Globe Biotech Limited, where he applies his expertise in vaccine development. His work has been instrumental in advancing the fight against infectious diseases, particularly in the context of the global pandemic.

Collaborations

Kakon Nag collaborates with several talented individuals in his field, including Juwel Chandra Baray and Maksudur Rahman Khan. Their combined efforts contribute to the innovative research and development at Globe Biotech Limited.

Conclusion

Kakon Nag's contributions to vaccine development highlight his role as a key innovator in the fight against coronavirus. His patent for a novel vaccine showcases the potential for scientific advancements in public health.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…